GlassScriptPhysician profile
Deepti S Moon
NPI 1134231871
$1,464.88
in general payments reported to CMS, 2019-2025
22 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.73 · 2024: $270 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.74 | 2025 | |
| Amgen INC. | $165.74 | 2024-2025 | Krystexxa, Uplizna |
| Travere Therapeutics, INC. | $161.35 | 2025 | Filspari |
| Aurinia Pharma U.S., INC. | $124.80 | 2024 | Lupkynis |
| Lilly USA, LLC | $87.94 | 2025 | Jardiance |
| Novo Nordisk INC | $75.32 | 2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $69.54 | 2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.36 | 2024-2025 | Jardiance |
| Cormedix INC. | $62.66 | 2025 | Defencath |
| Scpharmaceuticals INC. | $59.03 | 2025 | |
| Opko Pharmaceuticals, LLC | $55.30 | 2025 | Rayaldee |
| Ardelyx, INC. | $42.73 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $38.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.79 | 2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $34.29 | 2025 | Veltassa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $33.72 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $29.79 | 2025 | Envarsus |
| Kyowa Kirin, INC. | $27.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.45 | 2025 | Gattex |
| Glaxosmithkline, LLC. | $24.54 | 2025 | Benlysta |
| Nxstage Medical, INC. | $17.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.01 | 2025 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepti Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.